LQDA (Liquidia) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 26, 2026)


LQDA Liquidia Corp LQDA
67 GF Score
Price $76.91
GF Value $218.97
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Liquidia Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Liquidia's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

LQDA vs HIMS, LNTH, INDV: Margin of Safety % (DCF Earnings Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Liquidia's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Liquidia Margin of Safety % (DCF Earnings Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Liquidia's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Liquidia's Margin of Safety % (DCF Earnings Based) falls into.


LQDA
67GF Score
Liquidia Corp LQDA
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Liquidia (LQDA) Overvalued in 2026?

Based on GuruFocus' analysis, Liquidia stock appears to be undervalued. The current stock price of $76.91 is trading 64.9% below its estimated GF Value™ of $218.97. GuruFocus considers Liquidia to be Possible Value Trap.

Key valuation signals for LQDA:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: $218.97 vs. price of $76.91 (64.9% below fair value)
  • GF Score™: 67/100 with 6 warning signs

No single metric tells the full story. See the LQDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Liquidia Business Description

Other Exchanges LT4:Germany
Address 419 Davis Drive, Suite 100, Morrisville, NC, USA, 27560
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
67GF Score

Get the complete analysis for LQDA

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$76.91
Price
$218.97
GF Value